

# Prophylactic Beta-Blocker Therapy

**The Revised Cardiac Risk Index (RCRI) identifies patients at risk for peri-operative morbidity and mortality due to cardiac events**

- One point is assigned for each of the following risk factors
  - Thoracic Vascular Procedures
  - Abdominal Vascular Procedures
  - Supra-inguinal Vascular Procedures
  - Coronary Artery Disease
  - Diabetes Mellitus
  - Cerebrovascular Disease

**RCRI  $\geq 2$  defines the High risk patient**

- BB therapy in patients with RCRI scores  $\geq 2$  has been associated with reduced risk of peri-operative death
- Pt should receive BB if there are no contraindications to BB therapy

**Relative contra-indications to BB therapy**

- Allergy to BB
- Steroid-dependent and/or O<sub>2</sub>-dependent COPD
- De-compensated CHF
- EF  $< 20 - 30\%$
- HR  $< 50$  or history of 2nd or 3rd degree HB
- Post-carotid endarterectomy bradyarrhythmia

## Peri-operative BB Administration

**For patients already on chronic BB therapy**

- Continue oral BB on morning of surgery with sip of water

**For patients not previously on BB**

- Surgeon or primary care physician should administer Lopressor (Metoprolol) 25-50 mg BID on day before surgery
- BB should be held if: HR is  $< 50$  or SBP  $< 100$  torr, Sx of CHF, bronchospasm or 2nd or 3rd degree heart block

**Induction of Anesthesia**

- If HR  $> 80$  or within 20% of ischemic HR threshold
- Titrate up to 5 mg of metoprolol as part of induction

**Intra-operative Management**

- If HR  $> 100$  or Ischemia noted

- 1st Treat specific underlying cause of tachycardia
- Administer additional metoprolol in 1-2mg increments (maximum dosage 15mg IV)
- If ischemic ST segment changes persist despite BB therapy consider other therapeutic interventions

## **Emergency hypertension and tachycardia**

- 1st Treat specific underlying cause of tachycardia
- Treat with metoprolol or labetalol

## **Post-operative Management**

- Surgeon to order Metoprolol 25-50mg BID until the patient is discharged
- At discharge, patients' internist or cardiologist should determine whether BB therapy is continued